Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Opinion Article

Peptide Functionalised Nanocarriers for Bone Specific Delivery of PTH (1-34) in Osteoporosis

Author(s): Sagar Salave, Dhwani Rana and Derajram Benival*

Volume 11, Issue 3, 2021

Page: [142 - 148] Pages: 7

DOI: 10.2174/2468187312666211220112324

Price: $65

Abstract

Osteoporosis represents a major public health burden especially considering the aging population worldwide. Treatment modalities for osteoporosis are classified into two categories based on the effect on bone remodelling: anabolic drugs and antiresorptive drugs. Anabolic drugs are preferred as it stimulates new bone formation. Currently, PTH (1-34) is the only peptide-based drug approved as an anabolic agent for the treatment of osteoporosis by both USFDA as well as EMA. However, its non-specific delivery results in prolonged kidney exposure, causing hypercalcemia. Nanotechnology-based drug delivery systems functionalized by conjugating it with homing moieties, such as peptides, offer an advantage of targeted delivery with reduced off-target effects. Here, we propose an innovative and targeted nanovesicle approach to efficiently deliver PTH (1-34) to the bone surface using peptides as a homing moiety. The proposed innovative delivery approach will augment the specific interaction between the drug and bone surface without producing side effects. This will reduce the off-target effects of PTH (1-34), and at the same time, it will also improve the outcome of anabolic therapy. Therefore, we postulate that the proposed innovative drug delivery approach for PTH (1-34) will establish as a promising therapy for osteoporotic patients, specifically in postmenopausal women who are at greater risk of bone fracture.

Keywords: Osteoporosis , PTH (1-34) , anabolic agent , targeted drug delivery , nanovesicle , peptide ligand .

Graphical Abstract
[1]
Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet 2019; 393(10169): 364-76.
[http://dx.doi.org/10.1016/S0140-6736(18)32112-3] [PMID: 30696576]
[2]
Epidemiology of osteoporosis and fragility fractures, International Osteoporosis Foundation. Available from: https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures (Accessed on December 01, 2004).
[3]
Tabatabaei-Malazy O, Salari P, Khashayar P, Larijani B. New horizons in treatment of osteoporosis. Daru 2017; 25(1): 2.
[http://dx.doi.org/10.1186/s40199-017-0167-z] [PMID: 28173850]
[4]
Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 2017; 5(11): 898-907.
[http://dx.doi.org/10.1016/S2213-8587(17)30188-2] [PMID: 28689769]
[5]
Tu KN, Lie JD, Wan CKV, et al. Osteoporosis: a review of treatment options. P&T 2018; 43(2): 92-104.
[PMID: 29386866]
[6]
Russow G, Jahn D, Appelt J, Märdian S, Tsitsilonis S, Keller J. Anabolic therapies in osteoporosis and bone regeneration. Int J Mol Sci 2018; 20(1): 83.
[http://dx.doi.org/10.3390/ijms20010083] [PMID: 30587780]
[7]
Seeman E, Martin TJ. Antiresorptive and anabolic agents in the prevention and reversal of bone fragility. Nat Rev Rheumatol 2019; 15(4): 225-36.
[http://dx.doi.org/10.1038/s41584-019-0172-3] [PMID: 30755735]
[8]
Quattrocchi E, Kourlas H. Teriparatide: a review. Clin Ther 2004; 26(6): 841-54.
[http://dx.doi.org/10.1016/S0149-2918(04)90128-2] [PMID: 15262455]
[9]
Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ. Teriparatide for osteoporosis: importance of the full course. Osteoporos Int 2016; 27(8): 2395-410.
[http://dx.doi.org/10.1007/s00198-016-3534-6] [PMID: 26902094]
[10]
Dobnig H. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis. Expert Opin Pharmacother 2004; 5(5): 1153-62.
[http://dx.doi.org/10.1517/14656566.5.5.1153] [PMID: 15155114]
[11]
Eastell R, Walsh JS. Anabolic treatment for osteoporosis: teriparatide. Clin Cases Miner Bone Metab 2017; 14(2): 173-8.
[http://dx.doi.org/10.11138/ccmbm/2017.14.1.173] [PMID: 29263728]
[12]
Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007; 40(6): 1434-46.
[http://dx.doi.org/10.1016/j.bone.2007.03.017] [PMID: 17517365]
[13]
Jilka RL, Almeida M, Ambrogini E, et al. Decreased oxidative stress and greater bone anabolism in the aged, when compared to the young, murine skeleton with parathyroid hormone administration. Aging Cell 2010; 9(5): 851-67.
[http://dx.doi.org/10.1111/j.1474-9726.2010.00616.x] [PMID: 20698835]
[14]
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res 2003; 18(11): 1932-41.
[http://dx.doi.org/10.1359/jbmr.2003.18.11.1932] [PMID: 14606504]
[15]
Estell EG, Rosen CJ. Emerging insights into the comparative effectiveness of anabolic therapies for osteoporosis. Nat Rev Endocrinol 2021; 17(1): 31-46.
[http://dx.doi.org/10.1038/s41574-020-00426-5] [PMID: 33149262]
[16]
An JM, Shahriar SMS, Hwang YH, et al. Oral Delivery of Parathyroid Hormone Using a Triple-Padlock Nanocarrier for Osteoporosis via an Enterohepatic Circulation Pathway. ACS Appl Mater Interfaces 2021; 13(20): 23314-27.
[http://dx.doi.org/10.1021/acsami.0c22170] [PMID: 33587600]
[17]
Dave JR, Dewle AM, Mhaske ST, et al. Hydroxyapatite nanorods loaded with parathyroid hormone (PTH) synergistically enhance the net formative effect of PTH anabolic therapy. Nanomedicine 2019; 15(1): 218-30.
[http://dx.doi.org/10.1016/j.nano.2018.10.003] [PMID: 30343014]
[18]
Ponnapakkam T, Katikaneni R, Sakon J, Stratford R, Gensure RC. Treating osteoporosis by targeting parathyroid hormone to bone. Drug Discov Today 2014; 19(3): 204-8.
[http://dx.doi.org/10.1016/j.drudis.2013.07.015] [PMID: 23932952]
[19]
Bateman L, Vuppala S, Porada P, et al. Medical management in the acute hip fracture patient: a comprehensive review for the internist. Ochsner J 2012; 12(2): 101-10.
[PMID: 22778674]
[20]
Ponnapakkam T, Katikaneni R, Miller E, et al. Monthly administration of a novel PTH-collagen binding domain fusion protein is anabolic in mice. Calcif Tissue Int 2011; 88(6): 511-20.
[http://dx.doi.org/10.1007/s00223-011-9485-1] [PMID: 21512758]
[21]
Boskey AL. Bone composition: relationship to bone fragility and antiosteoporotic drug effects. Bonekey Rep 2013; 2: 447.
[http://dx.doi.org/10.1038/bonekey.2013.181] [PMID: 24501681]
[22]
Beniash E. Biominerals--hierarchical nanocomposites: the example of bone. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2011; 3(1): 47-69.
[http://dx.doi.org/10.1002/wnan.105] [PMID: 20827739]
[23]
Cölfen H. Biomineralization: A crystal-clear view. Nat Mater 2010; 9(12): 960-1.
[http://dx.doi.org/10.1038/nmat2911] [PMID: 21102512]
[24]
Gebauer D, Völkel A, Cölfen H. Stable prenucleation calcium carbonate clusters. Science 2008; 322(5909): 1819-22.
[http://dx.doi.org/10.1126/science.1164271] [PMID: 19095936]
[25]
Chai YC, Carlier A, Bolander J, et al. Current views on calcium phosphate osteogenicity and the translation into effective bone regeneration strategies. Acta Biomater 2012; 8(11): 3876-87.
[http://dx.doi.org/10.1016/j.actbio.2012.07.002] [PMID: 22796326]
[26]
Anderson HC. Matrix vesicles and calcification. Curr Rheumatol Rep 2003; 5(3): 222-6.
[http://dx.doi.org/10.1007/s11926-003-0071-z] [PMID: 12744815]
[27]
Aparicio S, Doty SB, Camacho NP, et al. Optimal methods for processing mineralized tissues for Fourier transform infrared microspectroscopy. Calcif Tissue Int 2002; 70(5): 422-9.
[http://dx.doi.org/10.1007/s00223-001-1016-z] [PMID: 12055658]
[28]
Jennings A, MacGregor A, Spector T, Cassidy A. Amino acid intakes are associated with bone mineral density and prevalence of low bone mass in women: evidence from discordant monozygotic twins. J Bone Miner Res 2016; 31(2): 326-35.
[http://dx.doi.org/10.1002/jbmr.2703] [PMID: 26334651]
[29]
Jack KS, Vizcarra TG, Trau M. Characterization and surface properties of amino-acid-modified carbonate-containing hydroxyapatite particles. Langmuir 2007; 23(24): 12233-42.
[http://dx.doi.org/10.1021/la701848c] [PMID: 17963411]
[30]
Palazzo B, Walsh D, Iafisco M, et al. Amino acid synergetic effect on structure, morphology and surface properties of biomimetic apatite nanocrystals. Acta Biomater 2009; 5(4): 1241-52.
[http://dx.doi.org/10.1016/j.actbio.2008.10.024] [PMID: 19083277]
[31]
Rautaray D, Mandal S, Sastry M. Synthesis of hydroxyapatite crystals using amino acid-capped gold nanoparticles as a scaffold. Langmuir 2005; 21(11): 5185-91.
[http://dx.doi.org/10.1021/la048541f] [PMID: 15896069]
[32]
Tavafoghi M, Cerruti M. The role of amino acids in hydroxyapatite mineralization. J R Soc Interface 2016; 13(123): 20160462.
[http://dx.doi.org/10.1098/rsif.2016.0462] [PMID: 27707904]
[33]
Ponnapakkam T, Katikaneni R, Suda H, et al. A single injection of the anabolic bone agent, parathyroid hormone-collagen binding domain (PTH-CBD), results in sustained increases in bone mineral density for up to 12 months in normal female mice. Calcif Tissue Int 2012; 91(3): 196-203.
[http://dx.doi.org/10.1007/s00223-012-9626-1] [PMID: 22806683]
[34]
Cheng H, Chawla A, Yang Y, et al. Development of nanomaterials for bone-targeted drug delivery. Drug Discov Today 2017; 22(9): 1336-50.
[http://dx.doi.org/10.1016/j.drudis.2017.04.021] [PMID: 28487069]
[35]
Nasim S, Vartak AP, Pierce WM, Taylor KG, Smith N, Crooks PA. 3-O-phosphate ester conjugates of 17-β-O-{1-[2-carboxy-(2-hydroxy-4-methoxy-3-carboxamido)anilido]ethyl}1,3,5 (10)-estratriene as novel bone-targeting agents. Bioorg Med Chem Lett 2010; 20(24): 7450-3.
[http://dx.doi.org/10.1016/j.bmcl.2010.10.023] [PMID: 21055931]
[36]
Neale JR, Richter NB, Merten KE, et al. Bone selective effect of an estradiol conjugate with a novel tetracycline-derived bone-targeting agent. Bioorg Med Chem Lett 2009; 19(3): 680-3.
[http://dx.doi.org/10.1016/j.bmcl.2008.12.051] [PMID: 19117754]
[37]
Segal E, Pan H, Benayoun L, et al. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011; 32(19): 4450-63.
[http://dx.doi.org/10.1016/j.biomaterials.2011.02.059] [PMID: 21429572]
[38]
Wang D, Sima M, Mosley RL, et al. Pharmacokinetic and biodistribution studies of a bone-targeting drug delivery system based on N-(2-hydroxypropyl)methacrylamide copolymers. Mol Pharm 2006; 3(6): 717-25.
[http://dx.doi.org/10.1021/mp0600539] [PMID: 17140259]
[39]
Wang D, Miller SC, Shlyakhtenko LS, et al. Osteotropic Peptide that differentiates functional domains of the skeleton. Bioconjug Chem 2007; 18(5): 1375-8.
[http://dx.doi.org/10.1021/bc7002132] [PMID: 17705416]
[40]
Huang L, Wang X, Cao H, et al. A bone-targeting delivery system carrying osteogenic phytomolecule icaritin prevents osteoporosis in mice. Biomaterials 2018; 182: 58-71.
[http://dx.doi.org/10.1016/j.biomaterials.2018.07.046] [PMID: 30107270]
[41]
Yarbrough DK, Hagerman E, Eckert R, et al. Specific binding and mineralization of calcified surfaces by small peptides. Calcif Tissue Int 2010; 86(1): 58-66.
[http://dx.doi.org/10.1007/s00223-009-9312-0] [PMID: 19949943]
[42]
Zhang G, Guo B, Wu H, et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 2012; 18(2): 307-14.
[http://dx.doi.org/10.1038/nm.2617] [PMID: 22286306]
[43]
Corrado A, Sanpaolo ER, Di Bello S, Cantatore FP. Osteoblast as a target of anti-osteoporotic treatment. Postgrad Med 2017; 129(8): 858-65.
[http://dx.doi.org/10.1080/00325481.2017.1362312] [PMID: 28770650]
[44]
Sun Y, Ye X, Cai M, et al. Osteoblast-Targeting-Peptide Modified Nanoparticle for siRNA/microRNA Delivery. ACS Nano 2016; 10(6): 5759-68.
[http://dx.doi.org/10.1021/acsnano.5b07828] [PMID: 27176123]

Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy